A Novel Engineered AAV-based Neoantigen Vaccine in Combination with Radiotherapy Eradicates Tumors

To overcome PD-1/PD-L1 inhibition in dendritic cells, the authors developed a novel adeno-associated virus neoantigen vaccine, modified with TLR9 inhibitory fragments, PD-1 trap, and PD-L1 miRNA, which extended the persistence of meAAV and activate neoantigen-specific T cell responses in immune-competent colorectal and breast cancer murine models.